BioCryst Pharmaceuticals (NASDAQ:BCRX) Raised to "Strong-Buy" at Wall Street Zen

Key Points

• Wall Street Zen upgraded BioCryst Pharmaceuticals from “buy” to “strong-buy,” while broader analyst coverage remains mixed: six analysts rate it Buy, four Hold, and one Sell. The consensus rating is “Hold,” with an average price target of $19.44.
• BioCryst reported quarterly earnings of $0.30 per share, exceeding the $0.15 consensus estimate, while revenue reached $218.25 million—up 33.6% year over year and above expectations.
• BCRX shares opened at $7.65, near the lower end of their 52-week range of $6.23 to $11.22. Institutional investors own approximately 85.88% of the company’s stock.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating in a report issued on Saturday, Wall Street Zen reports.

BCRX has been the topic of several other research reports. Weiss Ratings lowered shares of BioCryst Pharmaceuticals from a "hold (c)" rating to a "sell (d-)" rating in a research report on Tuesday, September 22nd. Needham & Company LLC restated a "buy" rating and issued a $16.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, September 8th. HC Wainwright reissued a "buy" rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Royal Bank Of Canada cut BioCryst Pharmaceuticals from an "outperform" rating to a "sector perform" rating and cut their target price for the stock from $13.00 to $11.00 in a research note on Thursday, September 10th. Finally, Cantor Fitzgerald raised their price objective on BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the stock an "overweight" rating in a research report on Tuesday, June 30th. Six equities research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $19.44.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.65 on Friday. BioCryst Pharmaceuticals has a fifty-two week low of $6.23 and a fifty-two week high of $11.22. The company has a fifty day moving average of $8.79 and a 200 day moving average of $9.10. The company has a market capitalization of $1.95 billion, a P/E ratio of -5.10 and a beta of 0.55.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.15. BioCryst Pharmaceuticals had a negative return on equity of 86.89% and a negative net margin of 40.90%. The company had revenue of $218.25 million for the quarter, compared to analysts' expectations of $183.28 million. During the same period in the previous year, the firm posted $0.15 earnings per share. The firm's revenue for the quarter was up 33.6% on a year-over-year basis. Analysts forecast that BioCryst Pharmaceuticals will post -2.28 EPS for the current year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Nykredit A S acquired a new stake in BioCryst Pharmaceuticals during the second quarter valued at approximately $27,000. IFP Advisors Inc lifted its holdings in shares of BioCryst Pharmaceuticals by 2,515.3% during the 2nd quarter. IFP Advisors Inc now owns 3,243 shares of the biotechnology company's stock valued at $32,000 after buying an additional 3,119 shares during the last quarter. Allworth Financial LP acquired a new position in BioCryst Pharmaceuticals during the second quarter worth $52,000. Pallas Capital Advisors LLC bought a new stake in BioCryst Pharmaceuticals during the second quarter worth approximately $101,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new position in BioCryst Pharmaceuticals during the 2nd quarter valued at $103,000. Institutional investors own 85.88% of the company's stock.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company focused on developing and commercializing oral medicines for rare and serious diseases. The company uses structure-based drug design and small-molecule research to develop therapies intended to address conditions with limited treatment options.

BioCryst's primary commercial product is Orladeyo (berotralstat), an oral medication used to prevent hereditary angioedema attacks in adults and pediatric patients aged 12 and older. The company also maintains a pipeline of investigational therapies for complement-mediated diseases and other rare disorders, including programs designed to inhibit components of the complement system.

Founded in 1986 and headquartered in Durham, North Carolina, BioCryst has historically conducted research and commercial activities in the United States and worked with international partners to make its products available in additional markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.